PARP1 and ovarian carcinoma: Olaparib was the first PARP inhibitor approved (in December 2014) for cancer therapy by the FDA (https://www.astrazeneca.com/media-center/press-releases/2014/lynparza-approved-us-fda-brca-mutated-ovarian-cancer-treatment-19122014.html#) and by the European Union (https://www.astrazeneca.com/media-center/press-releases/2014/lynparza-approved-european-union-brca-mutated-ovarian-cancer-treatment-18122014.html#).